Recent performance snapshot for Illumina (ILMN)

With no single headline event driving Illumina (ILMN) today, investors are instead looking closely at how the stock has traded recently and how that lines up with the company’s current financial profile.

Over the past month, Illumina’s share price is up about 13%, and the move over the past 3 months is stronger at roughly 35%. Year to date, the stock has gained about 20%, while the total return over the past year is about 85% despite a decline of roughly 64% over the past 5 years.

For Illumina, the recent 12.9% 1 month share price return and 35.0% 3 month share price return contrast with a 5 year total shareholder return that is down 63.7%. Recent momentum is therefore rebuilding from a much weaker long term base.

If you are looking beyond Illumina for other genomics and healthcare AI opportunities, this could be a good moment to scan the market using the 40 healthcare AI stocks

With Illumina trading at $160.97, which represents a discount of about 35% to one intrinsic value estimate but is above the average analyst price target, the key question is clear: is there still a buying opportunity here, or is future growth already priced in?

Most Popular Narrative: 18.3% Overvalued

The most followed Illumina narrative pegs fair value at $136.11 per share, which sits below the latest close of $160.97, and frames current pricing as ahead of that fair value anchor.

Operational efficiencies, disciplined cost controls, and targeted share repurchases have already resulted in notable operating margin and EPS improvements, and further scaling, along with tax headwinds turning into tailwinds, sets the stage for continued net margin and earnings growth over the next several years.

Want to see what earnings path justifies that price tag? This narrative leans on steady top line growth, firmer margins, and a future earnings multiple that has to hold up. Curious how those moving parts translate into that fair value call and what would need to go right for it to stick?

Result: Fair Value of $136.11 (OVERVALUED)

However, research funding pressure and ongoing China regulatory risk could still disrupt instrument demand and consumables revenue, challenging the optimistic earnings and margin path behind this narrative.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Cash Flows Point in a Different Direction

While the leading community narrative tags Illumina as 18.3% overvalued at $160.97 versus a $136.11 fair value, the SWS DCF model points in the opposite direction, with an estimated value of $247.18. That is a sizeable gap, so which set of assumptions do you find more realistic?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Illumina for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals so far, with both concerns and optimism in the picture, so it makes sense to look through the details yourself and move quickly to shape your own view by checking the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

Do not leave your watchlist anchored to a single stock when plenty of other opportunities are only a quick screen away on Simply Wall Street.

• Target potential mispricings by scanning for companies that score well on quality yet trade below intrinsic estimates using the 44 high quality undervalued stocks.
• Prioritise resilience by checking the 71 resilient stocks with low risk scores for stocks that combine lower risk scores with steadier fundamentals.
• Spot future contenders early by using the screener containing 20 high quality undiscovered gems before more investors start paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.